Brief: Harpoon Therapeutics To Present Interim Results From Phase 1 Trial Of HPN217 At The 64th ASH Meeting
03/11/2022 14:30
Nov 3 (Reuters) - Harpoon Therapeutics Inc HARP.O :
* HARPOON THERAPEUTICS TO PRESENT INTERIM RESULTS FROM PHASE
1
CLINICAL TRIAL OF T CELL ENGAGER HPN217 AT THE 64TH ASH ANNUAL
MEETING AND EXPOSITION
Source text for Eikon: ID:nGNX7ZJdmS
Further company coverage: HARP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harpoon Therapeutics
See all newsBrief: Harpoon Therapeutics Receives 17 Additional Demands Seeking Disclosures in Proxy Statement
U.S. RESEARCH ROUNDUP-Axonics, BlackRock, Credit Acceptance
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
Wrapup 1: Drugmakers kick off industry conference with two cancer deals